DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Ovarian Embryonal Carcinoma — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOvarian Embryonal Carcinoma maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ovarian embryonal carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
AKT serine/threonine kinase 1 (AKT1) — AKT1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet propanoylaminodrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7NH5 · 1.9 Å · ligand ~{N}-methyl-6-[4-[[4-[2-oxidanylidene-6-(propanoylamino)-3~{H}-benzimidazol-1-yl]piperidin-1-yl]methyl]phenyl]-5-phenyl-pyridine-3-carboxamide (UC8). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
癌症：英文版 · 2015 · 75 citations · open access
Pathobiology of ovarian carcinomas
AbstractOvarian tumors comprise a heterogeneous group of lesions, displaying distinct tumor pathology and oncogenic potentiel. These tumors are subdivided into three main categories: epithelial, germ cell, and sex-cord stromal tumors. We report herein the newly described molecular abnormalities in epithelial ovarian cancers (carcinomas). Immunohistochemistry and molecular testing help pathologists to decipher the significant heterogeneity of this disease. Our better understanding of the molecular basis of ovarian carcinomas represents the first step in the development of targeted therapies in the near future.
Journal Of Issues In Midwifery · 2021 · 0 citations · open access
Laporan Kasus : Pubertas Dini Akibat Kanker Ovarium Tipe Embrional
AbstractEmbryonic cell carcinoma (EC) is the first pluripotent cell identified and originates from a germ cell tumor called teratocarcinoma. Although rare, embryonal carcinoma is one of the most malignant cancers that can be found in the ovary. In this case report, a 4.5 year old girl was diagnosed with embryonal ovarian carcinoma after experiencing menstrual complaints for three months and developing pubic hair and breasts. Then the patient underwent a limited staging laparotomy. The results of clinical examination, radiology, and anatomical pathology showed results according to embryonal ovarian cancer. Chemotherapy with bleomycin etoposide and cisplatin for 3 cycles at 3 week intervals was performed after surgery. From this case, it can be concluded that physical examination and other examination are needed to diagnose embryonic ovarian cancer correctly.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
